Epidemiology of pyrazinamide-resistant tuberculosis in the United States, 1999-2009
Advanced Search
Select up to three search categories and corresponding keywords using the fields to the right. Refer to the Help section for more detailed instructions.
 
 
i

Superseded

This Document Has Been Replaced By:

i

Retired

This Document Has Been Retired

i

Up-to-date Information

This is the latest update:

Epidemiology of pyrazinamide-resistant tuberculosis in the United States, 1999-2009
  • Published Date:

    Jul 09 2013

  • Source:
    Clin Infect Dis. 57(8):1081-1093.
  • Language:
    English
Filetype[PDF-971.83 KB]


Details:
  • Alternative Title:
    Clin Infect Dis
  • Personal Author:
  • Description:
    Introduction Pyrazinamide (PZA) is essential in tuberculosis (TB) treatment. We describe the prevalence, trends and predictors of PZA resistance in Mycobacterium tuberculosis complex (MTBC) in the U.S. Methods We analyzed culture-positive MTBC cases with reported drug susceptibility tests (DST) for PZA in 38 jurisdictions routinely testing for PZA susceptibility from 1999-2009. National TB Genotyping Service data for 2004-2009 were used to distinguish Mycobacterium tuberculosis from Mycobacterium bovis and determine phylogenetic lineage. Results Overall 2.7% (2,167/79,321) of MTBC cases had PZA resistance, increasing annually from 2.0% to 3.3% during 1999-2009 (P<0.001), largely due to an increase in PZA monoresistance. PZA-monoresistant MTBC (versus drug-susceptible) was associated with age 0-24 years (adjusted prevalence ratio [aPR]=1.50, 95% CI 1.31-1.71), Hispanic ethnicity (aPR=3.52, 2.96-4.18), HIV infection (aPR=1.43, 1.15-1.77), extrapulmonary disease (aPR=3.02, 2.60-3.52), and normal chest radiograph (aPR=1.88, 1.63-2.16), and inversely associated with Asian (aPR=0.59, 0.47-0.73) and Black (aPR=0.37, 0.29-0.49) race. Among multidrug-resistant (MDR) cases 38.0% were PZA-resistant; PZA resistance in MDR MTBC was associated with female sex (aPR=1.25, 1.08-1.46) and previous TB diagnosis (aPR=1.37, 1.16-1.62). Of 28,080 cases with genotyping data, 925 (3.3%) had PZA resistance; 465/925 (50.3%) were M. bovis. In non-MDR M. tuberculosis cases, PZA resistance was higher in the Indo-Oceanic than the East Asian lineage (2.2% versus 0.9%; respectively; aPR=2.26, 1.53-3.36), but in MDR cases it was lower in the Indo-Oceanic lineage (22.0% versus 43.4%, respectively; aPR=0.54, 0.32-0.90). Conclusions Specific human and mycobacterial characteristics were associated with pyrazinamide-resistant MTBC, reflecting both specific subgroups of the population and phylogenetic lineages of the mycobacteria.
  • Subject:
  • Pubmed ID:
    23840002
  • Pubmed Central ID:
    PMC4578633
  • Document Type:
    Journal Article
  • Funding:
    CC999999/Intramural CDC HHS/United States
  • Place as Subject:
    United States
  • Collection(s):
    CDC Public Access
  • Main Document Checksum:
  • File Type:
No Related Documents.

You May Also Like:

  1. Filetype[PDF - 94.36 KB]
    Personal Author:
    Wang, Xiaomeng; Fu, Qian; Li, Zhijun; Chen, Songhua; Liu, Zhengwei; Nelson, Hugh; Yang, Qun; Jia, Zhongwei; Dye, Christopher;
    Published Date:
    Mar 2012
    Source:
    Emerg Infect Dis. 18(3):496-498.
    Description:
    To evaluate levels and trends in drug-resistant tuberculosis (TB) in Zhejiang Province, China, we conducted 1 survey in each of 3 years (1999, 2004, and 2008). We found that <5% of new cases were multidrug-resistant TB. The prevalence of multidrug-re...
    File Type:
    Filetype[PDF - 94.36 KB]
  2. Filetype[PDF - 793.93 KB]
    Personal Author:
    Ershova, Julia V.; Kurbatova, Ekaterina V.; Moonan, Patrick K.; Cegielski, J. Peter;
    Published Date:
    May 20 2014
    Source:
    Clin Infect Dis. 59(4):465-472
    Description:
    BackgroundResistance to second-line anti-tuberculosis drugs (SLD) severely compromises treatment options of drug-resistant tuberculosis (TB). We assessed the association between acquisition of resistance (AR) to second-line injectable drugs (SLI) or ...
    File Type:
    Filetype[PDF - 793.93 KB]
  3. Filetype[PDF - 556.49 KB]
    Personal Author:
    Sindani, Ireneaus; Fitzpatrick, Christopher; Falzon, Dennis; Suleiman, Bashir; Arube, Peter; Adam, Ismail; Baghdadi, Samiha; Bassili, Amal; Zignol, Matteo;
    Published Date:
    Mar 2013
    Source:
    Emerg Infect Dis. 19(3):478-480.
    Description:
    In a nationwide survey in 2011, multidrug-resistant tuberculosis (MDR TB) was found in 5.2% and 40.8% of patients with new and previously treated TB, respectively. These levels of drug resistance are among the highest ever documented in Africa and th...
    File Type:
    Filetype[PDF - 556.49 KB]
  4. Filetype[PDF - 269.88 KB]
    Personal Author:
    Modongo, Chawangwa; Zetola, Nicola M.;
    Published Date:
    Nov 2012
    Source:
    Int J Tuberc Lung Dis. 16(11):1561-1562
    File Type:
    Filetype[PDF - 269.88 KB]
  5. Filetype[PDF - 163.23 KB]
    Personal Author:
    Smith, Sarah E.; Pratt, Robert; Trieu, Lisa; Barry, Pennan M.; Thai, Dzung T.; Ahuja, Shama Desai; Shah, Sarita;
    Published Date:
    Oct 16 2017
    Source:
    Clin Infect Dis. 65(9):1437-1443.
    Description:
    BackgroundMultidrug-resistant tuberculosis (MDR TB) is an important global public health threat, but accurate estimates of MDR TB burden among children are lacking.MethodsWe analyzed demographic, clinical and laboratory data for newly-diagnosed pedia...
    File Type:
    Filetype[PDF - 163.23 KB]